Year 2010
January:
Day 25: Zydus Cadila’s Net Profit up by 114% in Q3
Day 4: Zydus Cadila to start clinical trials of H1N1 vaccine
Year 2009
December:
Day 31: Simayla becomes a 100% subsidiary of the Zydus Group
October:
Day 27: Zydus Cadila registers 39% increase in Net Profit in Q2
July:
Day 27: Zydus Cadila Q1 Net profit surges by 39%
Day 13: Zydus Cadila and Karo Bio’s research collaboration has generated promising lead compounds
June:
May:
Day 5: Zydus receives approval for Mycophenolate Mofetil tablets and capsules
April:
Day 28: Zydus Cadila’s Total Income up by whopping 26% in FY 09
Day 2: Zydus files IND application with the USFDA for ‘ZYT1’ a novel candidate to treat dyslipidemia
March:
Day 31: Zydus receives final approval for Topiramate Tablets
Day 30: Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines
Day 4: Zydus Research Centre Receives AAALAC Accreditation
January:
Day 29: New Approvals strengthen Zydus’ US product basket
Day 27: Zydus Cadila’s Total Income up by 31% in Q3
Year 2008
November:
Day 11: Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V.
October:
Day 22: Zydus Cadila registers 33% increase in Operating Net Profit in Q2
Day 20: Zydus receives approval for Risperidone Tablets
Day 16: Zydus files IND application for ‘ZYT1’ a novel candidate to treat dyslipidemia
Day 14: Zydus Cadila becomes the 1st Indian Pharma company to receive WHO accreditation for Rabies vaccine
September:
August:
Day 12: Zydus and WHO to develop next-generation biologicals to fight rabies
Day 01: Zydus receives approval for Bromocriptine Mesylate Capsules
July:
Day 29: Zydus Cadila Q1 Net profit up by 21%
Day 04: Cadila Healthcare to restructure its consumer business and create a single listed entity
June:
Day 16: Zydus scores with first day launch of Venlafaxine Hydrochloride in the US
Day 09: Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa
May:
Day 30: Zydus Cadila enters Spain, acquires Laboratorios Combix
Day 26: Zydus Cadila to market Benazepril in the US
Day 15: New Product Approvals for Zydus Cadila from USFDA
April:
Day 29: Zydus Cadila’s Net Sales up by whopping 27% in FY 08
March:
Day 11: Zydus and Nycomed expand scope of JV to create an API manufacturing hub for global supplies
February:
Day 15: Zydus Cadila firms up presence in Oncology segment with Nudoxa
Day 12: CRISIL reaffirms CADILA HEALTHCARE LIMITED’s ratings
Day 04: Zydus Cadila and Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases
January:
Day 31: Zydus Cadila’s Income up by 22.7% in Q3
Day 24: Zydus Cadila and Prolong Pharmaceuticals ink pact for collaboration in Drug Discovery and Development
Year 2007
October:
September:
Day 25: Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets
Day 06: Zydus Cadila receives USFDA approval for Carvedilol Tablets Launches product on the very same day
August:
July:
June:
Day 25: Zydus Cadila acquires Brazilian company Nikkho
Day 06: Zydus Cadila receives tentative approval for Topiramate tablets
May:
Day 15: Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India
Day 14: Zydus Cadila buys out JV stake in Sarabhai Zydus Animal Health Ltd
April:
Day 26: Zydus Cadila’s Net Profit up by whopping 53% in FY 07
Day 20: Zydus receives tentative approval for Losartan Potassium tablets
Day 19: Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan
March:
Day 17: New Approvals strengthen Zydus’ US product basket
Day 16: Zydus Cadila acquires Liva Healthcare, enters the 1500 cr. derma market
Day 12: Zydus Cadila receives USFDA approval for Paroxetine Tablets
February:
January:
Day 25: Zydus Research Centre to host International Symposium on Advances in Diabetes Therapy
Day 22: Zydus Cadila Q3 Net profit up by 66.4%
